SABS · SAB Biotherapeutics, Inc.
SAB Biotherapeutics Inc (SABS)
What's happening
- SABS is down 1.39% today, trading at $2.83. — Live quote
- Volume today (41,293) is well below its 3-month average of 685,630. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.28 actual vs. $-0.30 estimated (+5.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $314.1M | $207.0M | — | $15.5M | $12.7M |
| P/E | -52.10 | 18.38 | — | -0.47 | -0.46 |
| Price/Book | 1.46 | 0.91 | — | 1.29 | 0.59 |
| EV/EBITDA | -4.87 | -3.72 | — | — | — |
| ROE | -2.81% | 4.96% | — | -274.60% | -130.36% |
| ROA | -2.53% | 4.53% | — | -109.51% | -73.21% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -1795.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -4.0%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SABS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $263.1K | $944.6K |
| Operating income | -$23.4M | -$20.0M | -$12.7M | -$9.7M | -$10.8M | -$11.3M | -$10.2M | -$11.4M |
| Net income | -$22.5M | -$18.9M | $45.4M | -$10.1M | -$5.2M | -$10.3M | -$7.3M | -$5.0M |
| EPS (diluted) | $-0.28 | $-0.35 | $-0.21 | $-1.09 | $-0.56 | $-1.12 | $-0.79 | $-0.54 |
| EPS (basic) | $-0.28 | $-0.35 | $0.50 | $-1.09 | $-0.56 | $-1.12 | $-0.79 | $-0.54 |
| Operating margin | — | — | — | — | — | — | -$3.9K | -$1.2K |
| Net margin | — | — | — | — | — | — | -$2.8K | -$532 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $238.2M | $248.5M | $172.8M | $183.4M | $30.1M | $38.1M | $44.2M | $53.8M |
| Total liabilities | $23.4M | $21.2M | $21.3M | $18.4M | $18.1M | $16.7M | $18.2M | $16.9M |
| Stockholders' equity | $214.8M | $227.2M | $151.5M | $165.1M | $12.0M | $21.4M | $26.0M | $36.9M |
| Total current assets | $107.9M | $112.8M | $101.1M | $113.3M | $9.3M | $16.3M | $23.8M | $32.5M |
| Total current liabilities | $11.7M | $9.9M | $10.7M | $10.8M | $10.7M | $9.7M | $8.0M | $8.8M |
| Cash & equivalents | $8.3M | $20.5M | $10.5M | $29.4M | $3.7M | $5.6M | $8.9M | $9.2M |
| Marketable securities (current) | $94.4M | $86.9M | $86.1M | $81.5M | $2.0M | $7.2M | $11.9M | $21.2M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Marketable securities (non-current) | $105.3M | $110.2M | $46.9M | $50.6M | — | — | — | — |
| Property, plant & equipment | $14.2M | $13.8M | $13.3M | $13.1M | $13.9M | $14.6M | $15.4M | $16.1M |
| Accounts payable | $3.9M | $3.5M | $3.1M | $3.0M | $2.6M | $2.5M | $1.7M | $1.3M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $8.0K | $7.6K | $5.0K | $4.8K | $936 | $936 | $935 | $929 |
| Retained earnings | -$152.3M | -$129.8M | -$110.9M | -$94.0M | -$139.5M | -$129.4M | -$124.2M | -$112.8M |
| Accumulated other comprehensive income (loss) | -$930.0K | -$222.8K | $187.0K | $71.2K | -$15.8K | -$111.6K | -$135.4K | $52.1K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.8M | -$14.3M | -$16.8M | -$13.0M | -$7.2M | -$7.8M | -$9.5M | -$6.3M |
| Investing cash flow | -$4.9M | -$65.6M | -$1.7M | -$129.9M | $5.2M | $4.7M | $9.3M | -$1.2M |
| Financing cash flow | $2.4M | $89.9M | -$41.7K | $168.7M | -$174.0K | -$174.0K | $217.0K | -$674.1K |
| Free cash flow | -$11.4M | -$15.3M | -$17.7M | — | — | — | -$9.6M | -$6.4M |
| Capital expenditures | $1.6M | $983.3K | $933.2K | — | — | — | $55.4K | $100.3K |
| Depreciation & amortization | $800.0K | $731.0K | $2.2M | $700.0K | $800.0K | $756.6K | $2.7M | $900.0K |
| Share-based compensation | $7.2M | $5.5M | $3.2M | $800.9K | $627.0K | $613.0K | $674.1K | $1.0M |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | $674.9K | $114.1K | $324.5K | $336.3K | $137.8K | $684.2K | $590.4K | $134.6K |
| Purchases of investments | $13.0M | $139.3M | $12.0M | $129.9M | $52.1K | $70.9K | $1.3M | $4.8M |
| Tax withholding on stock comp | $4.4K | $4.6K | $4.3K | $5.0K | -$72 | $2.1K | $24.9K | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $1.3M | $2.2M | $23.9M | $60.9M |
| Operating income | -$49.0M | -$42.9M | -$38.1M | -$28.9M | -$13.4M |
| Net income | $13.3M | -$34.1M | -$42.2M | -$18.7M | -$17.1M |
| EPS (diluted) | $-0.79 | $-3.68 | $-7.64 | $-4.31 | $-0.63 |
| EPS (basic) | $0.22 | $-3.68 | $-7.64 | $-4.31 | $-0.63 |
| Operating margin | — | -$3.2K | -$1.7K | -$121 | -$22 |
| Net margin | — | -$2.6K | -$1.9K | -$78 | -$28 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jun '22 |
|---|---|---|---|---|---|
| Total assets | $172.8M | $44.2M | $83.9M | $50.9M | $59.4M |
| Total liabilities | $21.3M | $18.2M | $26.6M | $19.8M | $22.3M |
| Stockholders' equity | $151.5M | $26.0M | $57.3M | $31.1M | $37.1M |
| Total current assets | $101.1M | $23.8M | $58.9M | $22.1M | $28.0M |
| Total current liabilities | $10.7M | $8.0M | $10.8M | $15.0M | $16.4M |
| Cash & equivalents | $10.5M | $8.9M | $56.6M | $15.0M | $16.6M |
| Marketable securities (current) | $86.1M | $11.9M | $0 | — | — |
| Accounts receivable | — | — | $0 | $5.6M | $9.6M |
| Marketable securities (non-current) | $46.9M | — | — | — | — |
| Property, plant & equipment | $13.3M | $15.4M | $19.7M | $23.3M | $24.8M |
| Accounts payable | $3.1M | $1.7M | $945.9K | $3.7M | $4.9M |
| Accrued liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $4.8K | $935 | $929 | $510 | $4.4K |
| Retained earnings | -$110.9M | -$124.2M | -$90.1M | -$47.9M | -$32.9M |
| Accumulated other comprehensive income (loss) | $186.5K | -$135.4K | $26.4K | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$44.8M | -$34.3M | -$25.1M | -$23.5M | $2.0M |
| Investing cash flow | -$121.7M | -$12.0M | -$152.7K | -$2.1M | -$10.9M |
| Financing cash flow | $168.3M | -$1.2M | $66.8M | $1.1M | $35.9M |
| Free cash flow | -$45.7M | -$34.6M | -$25.3M | -$25.6M | -$9.0M |
| Capital expenditures | $933.2K | $337.3K | $197.2K | $2.2M | $10.9M |
| Depreciation & amortization | $3.0M | $4.7M | $3.7M | $3.2M | $1.5M |
| Share-based compensation | $5.2M | $2.9M | $2.4M | $2.7M | $2.3M |
| Change in accounts receivable | — | — | -$5.6M | -$2.5M | -$12.6M |
| Change in accounts payable | $1.5M | $923.3K | -$2.7M | -$779.4K | -$2.9M |
| Purchases of investments | $142.0M | $37.4M | — | — | — |
| Tax withholding on stock comp | $11.2K | $24.9K | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SABS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-09-19 to 2026-09-17
Recent transactions
- Most recent: Kropotova Alexandra (CHIEF MEDICAL OFFICER) — Tax withholding of 473 shares on 2026-09-17.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Kropotova Alexandra | CHIEF MEDICAL OFFICER | Tax withholding | 2026-09-17 | 473 |
| Moin Andrew | Reporting person | Option exercise | 2025-09-29 | 1,740,000 |
| Sessa Capital (Master), L.P. | Director | Option exercise | 2025-09-29 | 1,740,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-17 | Kropotova Alexandra | CHIEF MEDICAL OFFICER | Tax withholding | 473 | — |
| 2026-06-25 | Kropotova Alexandra | CHIEF MEDICAL OFFICER | Tax withholding | 988 | — |
| 2026-03-24 | Kropotova Alexandra | CHIEF MEDICAL OFFICER | Tax withholding | 988 | — |
| 2025-12-11 | Kropotova Alexandra | CHIEF MEDICAL OFFICER | Tax withholding | 988 | — |
| 2025-09-29 | Moin Andrew | Reporting person | Option exercise | 1,740,000 | $1.75 |
| 2025-09-29 | Sessa Capital (Master), L.P. | Director | Option exercise | 1,740,000 | $1.75 |
| 2025-09-19 | Kropotova Alexandra | CHIEF MEDICAL OFFICER | Tax withholding | 1,977 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:05 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 8-K | 2026-10-13 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-17 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-07 | 8-K | 2026-07-07 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-18 | 8-K | 2026-06-18 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-04 | 8-K | 2026-04-28 | View on SEC.gov → |
| 2026-04-22 | 8-K | 2026-04-22 | View on SEC.gov → |
| 2026-03-25 | 4 | 2026-03-24 | View on SEC.gov → |
| 2026-03-19 | 8-K | 2026-03-17 | View on SEC.gov → |
| 2026-03-10 | 8-K | 2026-03-10 | View on SEC.gov → |
Recent news
Headlines about SABS (SAB Biotherapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Is SAB Biotherapeutics (NASDAQ:SABS) In A Good Position To Invest In Growth?
Simply Wall Street · 2026-10-15 -
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
Yahoo · 2026-10-14 -
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
Yahoo · 2026-10-13 -
FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes
Benzinga · 2026-10-13 -
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
Yahoo Finance · 2026-09-22 -
SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha · 2026-09-10 -
SAB BIO to Participate in Upcoming Investor Conferences
Yahoo Finance · 2026-09-01 -
SAB Biotherapeutics Q2 Earnings Call Highlights
Yahoo Finance · 2026-08-07
No headlines in this category right now — try “All”.